Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix (NASDAQ:NBTX, Euronext:NANO) announced that trading of its ordinary shares on Euronext Paris will resume on May 21, 2026 at 3:30 p.m. Paris time.
Trading was halted earlier that day at the company’s request, linked to a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants.
Nanobiotix (NASDAQ:NBTX) requested a temporary halt of trading in its ordinary shares on Euronext Paris starting May 21, 2026, at 9:00 a.m. CEST.
The halt supports allocation confirmations and pricing for a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants, with trading expected to resume around 3:30 p.m. Paris time.
Nanobiotix (NASDAQ:NBTX) launched an approximately €75 million ($87 million) global follow-on offering of ADSs, ordinary shares and pre-funded warrants, subject to market conditions. The deal combines a U.S. public ADS offering with an international offering for qualified investors.
Pricing is expected before U.S. markets open on May 21, 2026, with a 30-day option for underwriters to buy up to 15% additional ADSs. Nanobiotix plans to use less than 10% of net proceeds for JNJ-1900 (NBTXR3), 50–60% for its Nanoprimer and other platforms, and 30–40% for general corporate purposes.
Nanobiotix (NASDAQ:NBTX) reported Part 1 data from the Johnson & Johnson-sponsored randomized Phase 2 CONVERGE trial of nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable NSCLC, presented at ESTRO 2026.
Early results in 7 patients showed ORR 85.7%, CRR 57.1%, and DCR 100% with concurrent chemoradiotherapy and durvalumab.
Nanobiotix (NASDAQ: NBTX) announced FDA acceptance of a protocol amendment to the pivotal NANORAY-312 global Phase 3 head and neck cancer study.
The amendment, submitted by Johnson & Johnson as global sponsor, removes the planned interim analysis, reduces the number of events for the final analysis, and moves the final analysis earlier. Nanobiotix says this could accelerate the global registration pathway for JNJ-1900 (NBTXR3) and anticipates the modified final analysis will read out in the timeframe of the originally planned interim analysis. Exact timing depends on when clinical events occur. Under the license agreement, Nanobiotix may be eligible for aggregate payments in the hundreds of millions tied to remaining development and regulatory milestones related to head and neck and lung cancer programs.
Nanobiotix (NASDAQ: NBTX) presented preclinical mouse data at AACR 2026 showing that pre-treatment with Nanoprimer before IV administration of LNP-delivered recombinant DNA (LNP-DNA) increased systemic bioavailability, reduced liver uptake and hepatic toxicity, and attenuated cGAS-STING inflammatory signaling versus LNP-DNA alone.
The findings support further evaluation of Nanoprimer sequenced with advanced extrahepatic LNP systems to potentially improve efficacy and safety.
Nanobiotix (Nasdaq: NBTX) published its voting rights and shares capital figures as of March 31, 2026. The company reports 48,517,630 shares outstanding and total voting rights of 50,165,132 (theoretical) and 50,143,014 (exercisable).
Listings: Euronext Paris (Compartment B) and Nasdaq. ISIN: FR0011341205.
NANOBIOTIX (NASDAQ: NBTX) reported full‑year 2025 results and a business update on March 31, 2026. Key highlights: €52.8M cash at year‑end with runway into early 2028 assuming receipt of the remaining $21M from a $71M royalty financing; €32.6M revenue; €24.0M net loss (−65% YoY).
Clinical progress included regulatory reclassification of JNJ‑1900 (NBTXR3), transfer of NANORAY‑312 sponsorship, CONVERGE dosing/data, multiple Phase 1/2 readouts, and Curadigm Nanoprimer IP/CMC advances. Conference call scheduled April 1, 2026.
NANOBIOTIX (NASDAQ: NBTX) announced first data from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer, presented March 30, 2026 at the 2026 European Lung Cancer Conference.
The poster reports an acceptable safety profile with no serious treatment-emergent adverse events and no adverse impact on patients' ability to continue planned therapy. Initial efficacy in seven patients showed ORR 71.4% and DCR 100%, compared with an estimated benchmark ORR of 45%–50%.
NANOBIOTIX (NASDAQ: NBTX) will report its fourth quarter and full year 2025 operational and financial results on March 31, 2026, after U.S. market close. A conference call and webcast will be held on April 1, 2026 at 8:00 AM EDT / 2:00 PM CEST.
Laurent Levy, CEO, and Bart van Rhijn, chief financial and business officer, will review year-end results and provide a business update. Webcast replay will be archived on the company website; investors may submit questions in advance via email.